Recent Finacing
Recent Raise
Ascentawits develops tumor‑microenvironment‑guided small‑molecule anticancer prodrugs, advancing AST‑3424—an AKR1C3‑selective prodrug with IHC companion diagnostic—through China Phase I/II trials and pipeline IP-backed candidates.
